Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.
Joon Young Hur, Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Gyeonggi-do, Republic of Korea

Main Body of the Abstract
Introduction
In amyloid light chain (AL) amyloidosis, bortezomib-based therapy can grant satisfactory (hematologic complete remission and/or organ response) and durable response in some patients who may then not proceed to autologous stem cell transplantation (ASCT). We retrospectively compare the outcomes of the patients who deferred ASCT with the patients who conducted ASCT after induction treatment.
Methods
We reviewed the outcomes of newly diagnosed ASCT-eligible AL amyloidosis patients who received bortezomib-based chemotherapy at a referral center between 2013 and 2020. Patients with biopsy-proven, systemic, AL amyloidosis, aged between 18-70 years, N-terminal pro-brain natriuretic peptide (NT-proBNP) <5,000 pg/mL, troponin-T (TNT) <0.06 ng/mL, high sensitivity TNT (hsTNT) <0.075 ng/mL, and ejection fraction (EF) > 40% were included. Major exclusion criteria was concurrent multiple myeloma defined.
Results
Of total 27 patients who were eligible for ASCT, 24 patients who had induction chemotherapy were enrolled in this study. The best hematologic response rate after induction treatment was 66.6% (n=16) complete remission (CR) and 33.3% (n=8) very good partial remissions (VGPR). There was no specific difference of progression free survival (PFS) according to ASCT (P=0.22). Median PFS did not differ with the presence of organ response (p=0.86). However, patients who achieve hematologic CR after induction chemotherapy had favorable PFS compared with patients who achieve hematologic VGPR (P=0.043). Swimmer's plot of each patients was shown in Figure.
Conclusions
In this study, we documented a high hematologic response rate with bortezomib based induction chemotherapy. We investigated if patients receiving bortezomib based chemotherapy could defer ASCT.

**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Joon Young Hur, Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Gyeonggi-do, Republic of Korea

**Main Body of the Abstract**
Introduction
In amyloid light chain (AL) amyloidosis, bortezomib-based therapy can grant satisfactory (hematologic complete remission and/or organ response) and durable response in some patients who may then not proceed to autologous stem cell transplantation (ASCT). We retrospectively compare the outcomes of the patients who deferred ASCT with the patients who conducted ASCT after induction treatment.
Methods
We reviewed the outcomes of newly diagnosed ASCT-eligible AL amyloidosis patients who received bortezomib-based chemotherapy at a referral center between 2013 and 2020. Patients with biopsy-proven, systemic, AL amyloidosis, aged between 18-70 years, N-terminal pro-brain natriuretic peptide (NT-proBNP) <5,000 pg/mL, troponin-T (TNT) <0.06 ng/mL, high sensitivity TNT (hsTNT) <0.075 ng/mL, and ejection fraction (EF) > 40% were included. Major exclusion criteria was concurrent multiple myeloma defined.
Results
Of total 27 patients who were eligible for ASCT, 24 patients who had induction chemotherapy were enrolled in this study. The best hematologic response rate after induction treatment was 66.6% (n=16) complete remission (CR) and 33.3% (n=8) very good partial remissions (VGPR). There was no specific difference of progression free survival (PFS) according to ASCT (P=0.22). Median PFS did not differ with the presence of organ response (p=0.86). However, patients who achieve hematologic CR after induction chemotherapy had favorable PFS compared with patients who achieve hematologic VGPR (P=0.043). Swimmer's plot of each patients was shown in Figure.
Conclusions
In this study, we documented a high hematologic response rate with bortezomib based induction chemotherapy. We investigated if patients receiving bortezomib based chemotherapy could defer ASCT.

The role of deferred autologous stem cell transplantation in patients with AL amyloidosis who had VGPR or CR after bortezomib-based induction therapy  PA140 (#90)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.